ArticleGastroenterology research and practice2016
Clinical Presentation, Risk Factors, and Treatment Modalities of Hepatocellular Carcinoma: A Single Tertiary Care Center Experience.
Article in Gastroenterology research and practice, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- Characteristics of hepatocellular carcinoma in a Saudi tertiary care center: a 10-year retrospective study.Hepatic oncology · 2026Article
- Review
- CircUCK2(2,3) promotes cancer progression and enhances synergistic cytotoxicity of lenvatinib with EGFR inhibitors via activating CNIH4-TGFα-EGFR signaling.Cellular & molecular biology letters · 2025Article
- The impact of alpha-fetoprotein (AFP), child-turcotte-pugh (CTP) score and disease staging on the survival of hepatocellular carcinoma (HCC) patients: a retrospective cohort from single oncology center.Oncology research · 2025Article
- Survival Outcomes and Prognostic Factors of Systemic Therapy for Advanced Hepatocellular Carcinoma: A Multidisciplinary Clinic Experience from Saudi Arabia.Journal of hepatocellular carcinoma · 2025Article
- Isolated calvarial lesion as the initial presentation of metastatic hepatocellular carcinoma: A case report and review of the literature.Surgical neurology international · 2025Article
- Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies.Journal of the Canadian Association of Gastroenterology · 2024Review
- Molecular characterization of plasma virome of hepatocellular carcinoma (HCC) patients.AMB Express · 2024Article
- Hepatocellular Carcinoma among Patients with Chronic Liver Disease in a Tertiary Care Centre: A Descriptive Cross-sectional Study.JNMA; journal of the Nepal Medical Association · 2024Article
- Article
- Treatment Patterns and Recommendations for Improving the Management of Hepatocellular Carcinoma in Saudi Arabia.Journal of hepatocellular carcinoma · 2024Article
- Application of artificial intelligence in the diagnosis of hepatocellular carcinoma.eGastroenterology · 2023Review
- Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment.Nature reviews. Gastroenterology & hepatology · 2023Review
- Update on Prevalence of Pain in Patients with Cancer 2022: A Systematic Literature Review and Meta-Analysis.Cancers · 2023Review
- Article
- Factors that Affect the Surveillance and Late-Stage Detection of a Newly Diagnosed Hepatocellular Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2021Observational
- Clinical Profile and Treatment of Hepatocellular Carcinoma: A Single-Center Experience.South Asian journal of cancer · 2021Article
- Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.Nature reviews. Gastroenterology & hepatology · 2021Review
- Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2020Article
- Ultrasound-Targeted Microbubble Destruction Mediated si-CyclinD1 Inhibits the Development of Hepatocellular Carcinoma via Suppression of PI3K/AKT Signaling Pathway.Cancer management and research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective. To investigate the risk factors, clinical characteristics, treatment modalities, and outcomes in Saudi patients with HCC and propose points for early detection of the disease. Methods. Patients were stratified according to underlying risk factors for the development of HCC. Barcelona Clinic Liver Cancer (BCLC) was used for cancer staging. Treatment was classified into surgical resection/liver transplantation; locoregional ablation therapy; transarterial embolization; systemic chemotherapy; and best supportive care. Results. A total of 235 patients were included. Males had higher tumor size and incidence of portal vein thrombosis. Viral hepatitis was a risk factor in 75.7%. The most common BCLC stages were B (34.5%) and A (33.6%), and the most common radiological presentation was a single nodule of less than 5 cm. Metastases were present in 13.2%. Overall, 77 patients (32.8%) underwent a potentially curative treatment as the initial therapy. The most commonly utilized treatment modality was chemoembolization with 113 sessions in 71 patients. The overall median survival was 15.97 ± 27.18 months. Conclusion. HCC in Saudi Arabia is associated with high prevalence of HCV. Potentially curative therapies were underutilized in our patients. Cancer stage BCLC-B was the most frequent (34.5%) followed by BCLC-A (33.6%). The overall median survival was shorter than other studies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.